What Refen Retard Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms. It is commonly used to help address symptoms that interfere with daily functioning and contribute to easing the overall symptom load.

This medication is considered relevant in conditions presenting with systemic or localized discomfort, such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout, and primary dysmenorrhea. It is relevant for managing symptoms that interfere with daily comfort, such as persistent pain, swelling, and joint stiffness.

It is relevant in contexts involving heightened systemic burden, often used during phases when symptoms become more noticeable, such as managing post-traumatic injuries or postoperative discomfort.

“It may assist with easing distress and helps improve day-to-day comfort during symptomatic periods.”

---

Key Focus: Supportive Relief for Stiffness
The prolonged-release form supports general well-being during symptomatic phases and may assist with easing physical stiffness and pain, which often interfere with daily functioning.

---

Regulatory References

1. Summary of Product Characteristics from the Irish Health Products Regulatory Authority

Refen Retard is an NSAID with eligibility rules defined by regulatory authorities to manage risks related to cardiovascular, gastrointestinal, and organ function. Use is permitted for adults and the elderly but requires particular caution in older adults due to an increased risk of adverse reactions [1.1, 2.1]. The prolonged-release tablets are generally not suitable for children and adolescents under 14 years of age [1.4].

The medicine is contraindicated (must not be used) in patients with established congestive heart failure (NYHA Class II–IV), ischemic heart disease, peripheral arterial disease, and cerebrovascular disease [1.1]. It is also prohibited for those with active gastric/intestinal ulcers, recurrent peptic ulceration, gastrointestinal bleeding, or severe hepatic or renal failure [1.3]. Patients with known hypersensitivity to diclofenac, aspirin, or other NSAIDs must not use the medicine [1.1].

Conditional use is required for patients with mild to moderate renal or hepatic impairment, a history of gastrointestinal disorders, or cardiovascular risk factors like hypertension, who must be closely monitored [1.3]. Refen Retard is contraindicated during the last trimester of pregnancy; use in the first two trimesters is not recommended and should be avoided unless clearly necessary [2.7]. Use is also generally not recommended while breastfeeding [3.1].

Interactions with other medicines and products

Refen Retard, which contains the active substance Diclofenac, has several formally documented interaction patterns established in regulatory documents from government health authorities.

Formal Contraindications and Restrictions

The medicine is officially contraindicated for use in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) should be avoided due to the documented increase in the risk of severe gastrointestinal (GI) toxicity. Use of alcohol is also cited as a factor that increases the risk for serious GI bleeding.

Pharmacodynamic and Exposure-Modifying Interactions

• Bleeding Risk Reinforcement: Concomitant use with Anticoagulants (such as Warfarin) or Antiplatelet agents significantly increases the risk of serious bleeding events due to additive pharmacodynamic effects. Similarly, co-administration with Corticosteroids increases the risk of serious GI ulceration.
• Efficacy Reduction: Diclofenac co-administration may diminish the antihypertensive and natriuretic effects of medicines such as ACE Inhibitors, ARBs, and Diuretics. This interaction is highlighted as being particularly relevant in elderly patients and those with volume depletion.
• Increased Drug Exposure: Co-administration with CYP2C9 inhibitors (e.g., Voriconazole) can formally increase the plasma concentrations of Diclofenac. Furthermore, Diclofenac can increase the serum concentration of both Lithium and Digoxin, requiring official monitoring of their plasma levels.
• Timing Note: Caution is noted for co-administration with Methotrexate within a 24-hour window, which may increase Methotrexate's exposure and potential toxicity.

The active substance, Diclofenac, acts by modulating biological pathways at the molecular level, affecting the activity of physiological responses. The core action involves the competitive and preferential inhibition of the Cyclooxygenase-2 ( COX-2) enzyme. This enzyme operates within the Arachidonic Acid Cascade and is responsible for producing prostanoid mediators, including Prostaglandin E2 ( PGE2). By blocking this synthesis, the drug initiates a cascade that results in the reduction of the inflammatory response's magnitude and alters the excitability of peripheral nociceptors.

Secondary to COX inhibition, the substance also acts to block certain voltage-dependent sodium channels ( Nav) on nerve cell membranes. This action modulates the nociceptive signaling pathway by physically reducing the nerve's capacity to transmit electrical impulses, thereby reducing the input of nociceptive signals toward the central nervous system.

The prolonged-release formulation ensures the active substance is released slowly and continuously. This process results in a steady and sustained influence on the targeted biological processes by maintaining constant, effective enzyme inhibition over an extended duration.

How to Use Refen Retard

Refen Retard is administered solely via the oral route as a prolonged-release tablet containing Diclofenac, typically in a 100 mg strength. The unique design of this formulation dictates its specific use pattern in clinical practice, focusing on a sustained effect over a full day.

---

Official Administration Protocol

The standard adult dosing schedule is once daily (100 mg), which is consistent with the extended-release characteristics of the drug. Adherence to this frequency is crucial, as the tablet is designed to maintain consistent drug levels over 24 hours.

Instruction Category	Procedural Requirement
Tablet Handling	The tablet must be swallowed whole with a sufficient amount of water.
Integrity Restriction	It is strictly prohibited to crush, chew, or divide the prolonged-release tablet, as this action compromises the time-release mechanism.
Timing & Meals	Administration can occur with or after food to aid tolerability.
Dose Constraint	The maximum dose for this formulation is generally 100 mg per day; the core principle is to use the lowest effective dose for the shortest duration necessary.

---

Population-Specific Use

For older adults, medical labeling recommends initiating treatment at the lowest possible dose to account for potential sensitivities. Furthermore, this prolonged-release strength is not typically suitable for use in children or adolescents.

If a dose is missed, standard practice involves skipping the missed dose and continuing with the regular schedule if it is near the time for the next dose, emphasizing that a double dose must never be taken.

Evidence for Chronic Inflammatory Conditions

The research base for Refen Retard’s active ingredient, Diclofenac, in chronic conditions includes numerous short-term, randomized controlled trials (RCTs) and observational studies for conditions like rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Studies examined outcomes related to physical discomfort, including pain intensity, joint stiffness, and outcomes reflecting daily functioning. While long-term observational cohorts exist, the follow-up durations for many specific prolonged-release trials were limited, and long-term effects are not fully established regarding functional outcomes.

---

Evidence for Acute Symptomatic Relief and Primary Dysmenorrhea

Research has explored conditions associated with acute or disruptive episodes, such as postoperative discomfort and primary dysmenorrhea (menstrual cramps). Studies monitored outcomes describing episodic changes, focusing on the time to initial relief and the use of supplemental pain medicine. A key limitation is that evidence for rapid relief was often observed in trials using immediate-release forms of the drug. Data for the prolonged-release formulation specifically is limited when examining the immediate hours following acute pain onset or for conditions requiring intermittent use.

---

Research Gaps and Areas of Uncertainty

The evidence quality varies across studies, and findings were mixed when pooling data from different formulations. While specific attention was given to older adults in observational settings, data for other special groups, such as children, remain insufficient. Overall, long-term effects are not fully established for functional outcomes, and there is a notable absence of specific published data isolating the performance of the prolonged-release form in every high-risk patient subgroup. These findings describe group patterns, not personal outcomes.

Key Studies & References

1. Summary of Product Characteristics for Diclofenac Sodium 75mg Prolonged-release Tablets (Refen Retard)
2. Osteoarthritis: care and management. NICE Guideline [NG240]

Common questions about Refen Retard (FAQ)

Q: How long does it typically take for Refen Retard to start working?

A: As an extended-release formulation, Refen Retard is specifically designed to release the medicine slowly and continuously over many hours, aiming for a sustained effect. This means the time it takes to reach the highest concentration in the blood is delayed compared to immediate-release forms. The goal is long-lasting relief rather than rapid onset.

Q: How does the extended-release feature change the way the drug is absorbed?

A: The prolonged-release feature is achieved through a controlled-release tablet design. This design ensures that the active ingredient is released slowly and consistently over an extended duration. This mechanism is intended to prolong the absorption time, which helps achieve a consistent therapeutic influence over an extended period.

Q: How does Refen Retard differ from the immediate-release version?

A: Refen Retard, the prolonged-release tablet, is designed to be taken once daily for sustained symptomatic management of conditions requiring constant relief. In contrast, immediate-release formulations of the same active substance are generally designed for rapid absorption and are typically used for conditions that require faster, intermittent relief.

Q: Does Refen Retard interact with blood pressure medications?

A: Official documents indicate that Refen Retard's active ingredient, Diclofenac, may diminish the desired effects of certain blood pressure medicines. Specifically, interactions have been documented with ACE inhibitors, Angiotensin II Receptor Blockers (ARBs), and Diuretics. This suggests co-administration may reduce the blood pressure-lowering effect of those medicines.

Q: Can Refen Retard be taken with vitamins or supplements?

A: Government health advisories generally state that there is insufficient official information to confirm the safety of taking Diclofenac with all complementary medicines, herbal remedies, and nutritional supplements. This is because these products are not tested in the same way as prescription medicines, and therefore, potential interactions are not fully ruled out.

Q: Are there particular side effects that are more common than others?

A: Regulatory labeling classifies adverse reactions by frequency. Side effects officially classified as common (affecting more than 1 in 100 people) typically include headache, dizziness, nausea, vomiting, diarrhea, stomach pain, and rash. These are the effects officially classified as common, based on regulatory documentation.

Q: What information is available about Refen Retard's use in pregnancy?

A: Official regulatory documents state that its use is contraindicated (must not be used) in the third trimester of pregnancy due to the documented risk of fetal harm. Use during the first and second trimesters is also not recommended unless the potential benefit justifies the potential risk, based on official safety warnings.

Q: What should I do if I miss a dose of Refen Retard?

A: Regulatory guidance on missed doses for this prolonged-release formulation advises to skip the missed dose if it is close to the time for the next scheduled dose. Regulatory guidance emphasizes that a double dose should never be taken to compensate for a missed dose.

Q: Is Refen Retard the same type of medicine as ibuprofen?

A: Refen Retard contains Diclofenac, while Ibuprofen is a separate medicine. Regulatory classification lists both the active substance in Refen Retard, Diclofenac, and Ibuprofen in the same pharmacological class, the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Official documents advise against using them together.

Q: Can Refen Retard be used for headaches?

A: The specific prolonged-release formulation (Refen Retard) is typically indicated for inflammatory conditions and sustained symptomatic relief. Official documents describe the use of the active ingredient, Diclofenac, for some pain relief, but the indication for a specific type of headache depends on the formulation.

Q: Is it normal to feel drowsy after taking Refen Retard?

A: Official adverse event listings for Diclofenac include central nervous system effects such as dizziness and drowsiness (somnolence). Because these effects are documented, experiencing them is listed as a possible side effect of the medicine.

Q: Is it normal for Refen Retard to cause mild nausea?

A: Yes, official safety documents list nausea as a common adverse reaction for Diclofenac. This means it is among the effects most frequently reported by patients in studies and post-market surveillance.

Q: Can Refen Retard interact with diabetes medications?

A: Yes, regulatory documents indicate that when Diclofenac is used with oral hypoglycemic agents (medicines used to lower blood sugar in diabetes), caution is advised. This is because an interaction may occur, requiring close monitoring of blood sugar levels.

Q: Can Refen Retard make you sensitive to sunlight?

A: Official adverse event listings for the active ingredient, Diclofenac, include a risk of photosensitivity, which is an increased sensitivity to sunlight. This means that protection from sun exposure is a consideration as a documented possible side effect.

Q: Are there any lifestyle restrictions while taking Refen Retard?

A: Official documents explicitly cite that the use of alcohol is a factor that increases the risk for serious gastrointestinal bleeding while using this medicine. Due to this elevated risk, limiting alcohol intake is addressed in official documents.

Q: Does Refen Retard affect sleep patterns?

A: Official adverse event listings for the active substance include certain central nervous system effects, such as drowsiness and documented instances of dream abnormalities. These reported effects may be related to changes in a patient's sleep patterns.

Q: Does Refen Retard treat the underlying condition or just the symptoms?

A: Refen Retard is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is described in official sources as providing symptomatic management. Its action reduces the effects of inflammation and pain signaling, but it is not generally described as modifying the course of the underlying disease itself.

Q: Do studies show Refen Retard is effective for back pain?

A: Regulatory information for the active substance, Diclofenac, indicates that it is used to relieve discomfort and inflammation in conditions like backache, as well as sprains and strains. This suggests that the medicine has a documented indication for these types of painful conditions.

Official Storage and Disposal Requirements

Regulatory documentation defines specific storage and handling constraints for Refen Retard to ensure stability and efficacy. These requirements are based on stability testing and are mandatory.

Requirement Area	Official Instructions
Temperature	Store below 25 C (Room Temperature).
Protection	Keep protected from both moisture and light.
Packaging	Keep the tablets in the original container or blister packaging until the time of use.
Child Safety	Must be stored strictly out of the sight and reach of children.
Disposal	Do not dispose of expired or unused Refen Retard in household trash or wastewater. Return the product to a pharmacy or a designated pharmaceutical waste collection point in accordance with local regulations.